Literature DB >> 30610217

Targeting progression in multiple sclerosis - an update.

Maria A Rocca1, Massimo Filippi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30610217     DOI： 10.1038/s41582-018-0127-3

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  3 in total

1.  Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.

Authors:  Chiara Tremolanti; Chiara Cavallini; Laurence Meyer; Christian Klein; Eleonora Da Pozzo; Barbara Costa; Lorenzo Germelli; Sabrina Taliani; Christine Patte-Mensah; Ayikoé-Guy Mensah-Nyagan
Journal:  Mol Neurobiol       Date:  2022-01-11       Impact factor: 5.590

2.  Loss of Neurologic Reserve in Progressive Multiple Sclerosis: A Paradigm Shift?

Authors:  Joep Killestein; Maria Liguori
Journal:  Neurol Clin Pract       Date:  2021-08

3.  Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis.

Authors:  Luca Prosperini; Serena Ruggieri; Shalom Haggiag; Carla Tortorella; Carlo Pozzilli; Claudio Gasperini
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.